Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227614 | 1.00 | CASP2 (0.51) | CASP2EPHX1NAAADNM1FAAH | |
| SCHEMBL22318122 | 0.98 | CASP2 (0.49) | CASP2EPHX1NAAADNM1FAAH | |
| SCHEMBL22872802 | 0.89 | NAMPT (0.39) | CASP2EPHX1NAAADNM1MEN1 | |
| SCHEMBL23589714 | 0.89 | NAMPT (0.39) | CASP2EPHX1NAAADNM1MEN1 | |
| SCHEMBL23589907 | 0.89 | NAMPT (0.39) | CASP2EPHX1NAAADNM1MEN1 | |
| SCHEMBL23589671 | 0.89 | NAMPT (0.39) | CASP2EPHX1NAAADNM1MEN1 | |
| SCHEMBL23589692 | 0.89 | NAMPT (0.39) | CASP2EPHX1NAAADNM1MEN1 | |
| SCHEMBL23589715 | 0.89 | NAMPT (0.39) | CASP2EPHX1NAAADNM1MEN1 | |
| SCHEMBL22301097 | 0.87 | KMT2A (0.39) | CASP2EPHX1DNM1MEN1KMT2A | |
| SCHEMBL25089984 | 0.86 | KMT2A (0.36) | CASP2EPHX1NAAADNM1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CASP2 1113/4885EPHX1 1508/4885NAAA 2733/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CASP2 1113/4885EPHX1 1508/4885NAAA 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.